Assessment of the Safety, Efficacy, and Benefit of Empagliflozin in Patients With Type 2 Diabetes Mellitus (T2DM) and Heart Failure With Reduced Ejection Fraction (HFrEF) at High Risk for Cardiovascular Events

Ruba Towiargi; Lama  Fetyani; Naila  Aljahdali; Adnan  Alnofeie; Yahya  Alnoamy; Reham  Ghandorah; Abrar  Abduljawad; Njood  Alharbi; Alanoud  Alghanmi; Hala   AlButi; Ruba S. Towiargi; Lama  Fetyani; Naila  Aljahdali; Adnan  A. Alnefaie; Yahya  Alnoamy; Reham  M. Ghandorah; Abrar  S. Abduljawad; Njood  A. Alharbi; Alanoud  Alghanmi; Hala   AlButi

doi:10.7759/cureus.33070

Enter your email address to receive your free PDF download.

Please note that by doing so you agree to be added to our monthly email newsletter distribution list.

Sign up for Cureus

or

First name

Last name

Email

Password

Specialty

Email Communication and Personal Data

Cureus personal data will never be sold to third parties and will only be used to enrich the user experience and contact you in direct relation to the application. I agree to opt in to this communication.

Learn more

Learn more

Learn more

Learn more

Learn more

Ongoing Competitions

Enter your email address to receive your free PDF download.

Sign in to Cureus

Sign up for Cureus

Email Communication and Personal Data

Download Cureus Media Kit